| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Brave Health is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We build applications that use speech and fine motor to detect subtle changes in brain health. We are rooted in neuroscience with an award winning, first to market technology platform that turns the devices we use every day into objective brain health monitors.
Our commitment is well-established, so we decided to shorten our name. Catholic Health Services of Long Island is now Catholic Health.
Visiting Nurse Service is a Northport, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.